Objective: The aim of our study was to determine the relation of particular genetic variants in selected genes (GSTM1, GSTT1 null genotypes; rs1695 GSTP1; rs10735781 EVI5) to the risk of multiple sclerosis (MS) development and find out the possible association with disease disability progression rate. Material and methods: Our study included 202 MS patients and 174 healthy control volunteers. MS patients were divided according to disability progression rate to three groups - slowly progressing, mid-rate progressing and rapidly progressing. All DNA samples were isolated from venous blood. Genotyping was performed by PCR-RFLP and multiplex PCR. Results: Our analysis showed that GSTT1 null genotype (OR 0.56; 95%CI 0.33 -0.95; p=0.04) and GSTM1, GSTT1 double null genotype (OR 0.32; 95%CI 0.14 - 0.74; p=0.006) are potentially protective in relation to MS. We observed similar result in GSTT1 null genotype in association with mid-rate progression (OR 0.48; 95%CI 0.24 - 0.97; p=0.05). Frequency of GSTM1 and GSTT1 double null genotype is significantly lower in subgroup of MS patients with progression rate defined as slow (OR 0.22; 95%CI 0.05 - 0.98; p=0.05) and middle (OR 0.33; 95%CI 0.11 - 0.99; p=0.045). We did not show any significant association of genetic changes rs1695 in GSTP1 and rs10735781 in EVI5 with MS or rate of disease progression. Conclusions: Genetic basis of multiple sclerosis is still not fully elucidated. Further research may clarify our results and confirm the value of studied factors for clinical practice.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Nischwitz S Muller-Myhsok B Weber F. Risk conferring genes in multiple sclerosis. FEBS Lett. 2011; 585 (23): 3789-97.
2. Sawcer S Hellenthal G Pirinen M Spencer CCA Patsopoulos NA Moutsianas L et al. The International Multiple Sclerosis Genetics Consortium (IMSGC) Wellcome Trust Case Control Consortium 2 (WTCCC2). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476 (7359): 214-9.
3. Zhang Q Lin CY Dong Q Wang J Wang W. Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies. Autoimmun Rev. 2011; 10 (8): 474-81.
4. Faitar SL Sossey-Alaoui K Ranalli TA Cowell JK. EVI5 protein associates with the INCENP-aurora B kinase-survivin chromosomal passenger complex and is involved in the completion of cytokinesis. Exp Cell Res. 2006;312 (12): 2325-35.
5. Mowry EM Carey RF Blasco MR Pelletier J Duquette P Villoslada P et al. Multiple sclerosis susceptibilitygenes: associations with relapse severity and recovery. PLoS One. 2013; 8 (10): e75416.
6. Roxburgh RH Seaman SR Masterman T Hensiek AE Sawcer SJ Vukusic S et al. Multiple sclerosis severityscore: using disability and disease duration to rate disease severity. Neurology. 2005; 64 (7): 1144-51.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33 (11) :1444-52.
8. Čierny D Hanyšova S Michalik J Kantorova E Kurča E Škereňova M Lehotsky J. Genetic variants in interleukin 7 receptor chain (IL-7Ra) are associated with multiple sclerosis risk and disability progression in Central European Slovak population. J Neuroimmunol. 2015; 282: 80-4.
9. Čierny D Michalik J Kurča E Dobrota D Lehotsky J. FokI vitamin D receptor gene polymorphism in association with multiple sclerosis risk and disability progression in Slovaks. Neurol Res. 2015; 37 (4): 301-8.
10. Alexoudi A Zachaki S Stavropoulou C Gavrili S Spiliopoulou C Papadodima S et al. Possible Implication of GSTP1 and NQO1 Polymorphisms on Natalizumab Response in Multiple Sclerosis. Ann Clin Lab Sci. 2016; 46 (6): 586-591.
11. Mann CL Davies MB Boggild MD Alldersea J Fryer AA Jones PW et al. Glutathione S-transferase polymorphisms in MS: their relationship to disability. Neurology. 2000; 54(3): 552-7.
12. Živković M Životić I Dinčić E Stojković L Vojinović S Stanković A. The glutathione S-transferase T1 deletion is associated with susceptibility to multiple sclerosis. J Neurol Sci. 2013; 334(1-2):6-9.
13. Stavropoulou C Korakaki D Rigana H Voutsinas G Polyzoi M Georgakakos VN et al. Glutathione-Stransferase T1 and M1 gene polymorphisms in Greek patients with multiple sclerosis: a pilot study. Eur J Neurol. 2007; 14(5): 572-4.
14. Bačić Baronica K Mlinac K Petlevski R Ozretić D Vladić A Kalanj-Bognar S Zuntar I. Progression of multiple sclerosis is associated with gender differences in glutathione S-transferase P1 detoxification pathway. Acta Neurobiol Exp (Wars). 2014; 74(3): 257-65.
15. Hafler DA et al. INTERNATIONAL MULTIPLE SCLEROSIS GENETICS CONSORTIUM 1. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007; 2007357 (9): 851-62.
16. Hoppenbrouwers IA Aulchenko YS Ebers GC Ramagopalan SV Oostra BA Van Duijn CM Hintzen RQ. EVI5 is a risk gene for multiple sclerosis. Genes Immun. 2008; 9 (4): 334-7.
17. Johnson BA Wang J Taylor EM Caillier SJ Herbert J Khan OA et al. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun. 2010; 11 (4): 343-50.